<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Krucoff, Mitchell W.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel Design Changes in DES Not Necessarily Better until Proven So</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">24-24</style></pages><abstract><style  face="normal" font="default" size="100%">A drug-eluting stent is a “combination product” in which changes to one component may affect others; small alterations to strut thickness and geometry, polymer, drug, dose, and kinetics may result in big outcome changes, for better or worse. This article discusses the many factors involved in the development and deployment of novel stents.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>